Fintech Company Wisor AI Secures $8 Million in Seed Funding to Modernize Global Supply Chain
7.2.2023 14:00:00 CET | Business Wire | Press Release
Wisor AI, an advanced freight booking software solution, has raised $8 million in a seed funding round led by Team8. The funding will expedite Wisor’s mission to digitize the global supply chain industry and empower freight forwarders to plan, price and book a shipment in seconds instead of hours or days.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005326/en/
Wisor's Co-Founders. From left to right: Ido Karavany, Co-founder & CTO; Raz Ronen, Co-founder & CEO; and Eiran Bolless, Co-founder & VP of Data & Analytics. (Photo: Business Wire)
Amid recent sectoral innovations geared towards different players in the value chain such as marketplaces and digital-first freight companies, Wisor has developed a software solution tailored specifically to the needs of freight forwarders themselves – the ones servicing the majority of freight volume today.
Wisor’s plug and play solution automates both the cumbersome, manual process of aggregating pricing data as well as the optimization of shipping routes across the global freight ecosystem, including airlines, ocean liners, trucking, and rail companies. This allows freight forwarders to do more with less, improving response rates, and freeing capacity to grow their business. In addition to pricing automation, Wisor’s advanced algorithms continuously optimize pricing in the background - even after the booking has been placed - presenting further opportunities for freight forwarders to cut costs and improve their margins.
Wisor’s platform provides its global customers a one-stop solution that organically integrates into their existing systems and workflows. By digitizing routing, pricing and quoting, the platform would also be able to extend to additional value added services such as payments, financing and insurance.
The opportunity to transform the freight forwarding market is massive. Today there are roughly 300,000 freight forwarders globally, including 100,000 in the US alone, handling $23.3 trillion in goods delivered to consumers. This huge market is ripe for disruption, as it lacks the tools and technology required to bring forwarding operations into the digital era. Wisor is focused on empowering freight forwarders to compete in a challenging environment suffering from high price volatility and reliance on outdated manual processes.
“As an entrepreneur, I am fascinated by traditional industries that still heavily rely on manual processes and legacy tools,” said Raz Ronen, CEO and Co-Founder of Wisor AI. “The complexity of supply chain management has become pronounced in recent years due to global disruptions caused by COVID-19. Wisor found a way to digitize this industry without requiring freight forwarders to fundamentally change the way they operate today, making the adoption seamless, while enjoying the benefits of digitization.”
“Team8 is excited to lead the seed funding round for Wisor AI in order to support their mission to bring the supply chain into the digital era," said Hadar Siterman Norris Partner at Team8 Capital. “With a clear vision to offer an end-to-end solution for all freight forwarding processes, Wisor is uniquely positioned to become a key player in this large, highly fragmented and increasingly complex industry. We are looking forward to working with Raz, Eiran, Ido and the Wisor team, who bring years of expertise in supply chain management, machine learning, data and AI to the table.”
Wisor’s funding round also included participation from Ocean Azul and Hico Investment Group, as well as pre-seed investors fresh.fund, Atooro Fund, The Dock, Seed IL Ventures, and Izaki Ventures.
About Wisor
Wisor AI is an advanced freight booking software solution geared towards modernizing the global freight forwarding industry which manages the delivery of everything we use, wear and consume. The company’s plug & play solution provides a global automated quoting solution, allowing freight forwarders to generate quotes and communicate with clients automatically and within minutes. Wisor's seamless integration and cutting-edge technology can empower more than 300,000 traditional freight forwarding companies to increase efficiency, cut costs and gain profitability. The company was founded in 2021 and is headquartered in Tel Aviv, Israel. To learn more, visit www.wisor.ai/
About Team8
Team8 is a venture group that builds and invests in the most innovative technologies in the fields of fintech, cyber, data, and digital health. We leverage deep domain expertise, cutting-edge technology, and first-hand company-building experience to partner with entrepreneurs in founding globally-successful companies, while also investing in early-stage companies that are active in the Group's fields of interest. Visit www.team8.vc to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005326/en/
Contact information
Caliber Corporate Advisers
Nicole Lombardo
nicole@calibercorporate.com
6313579593
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
